Morningstar

BeiGene Ltd ADR BGNE

Morningstar Rating
Unlock
Stock XNAS Rating as of
$222.21 −2.47 (1.10%)
View Full Chart
As of Cboe BZX Real-Time Price Open

Company Report

View Archive

BeiGene: Initiating Coverage With a No-Moat Rating; Shares Fairly Valued

Yurou Zheng

We initiate coverage of BeiGene with a fair value estimate of HKD 125 per share and a no-moat rating. Focusing on oncology therapeutics, BeiGene is a commercial-stage biotechnology company with global revenue. We think the shares are fairly valued and investors should wait for a better entry point. The key upside to our valuation depends on patent-protected portfolio expansion rather than indication expansion from existing commercialized drugs.

Read Full Report

Price vs Fair Value

View History
BGNE is trading within a range we consider fairly valued.
Price
$225.65
Fair Value
$281.82
Uncertainty
High
1-Star Price
$876.49
5-Star Price
$179.27
Economic Moat
Vscwf
Capital Allocation
—

Bulls Say, Bears Say

Bulls

Price cuts on its existing drugs are more lenient, which may boost its gross margin.

Bears

Additional fundraising via equity may lower its current shareholder value.

Show More

News

View All

Trading Information

Previous Close Price
$224.68
Day Range
$222.21–226.20
52-Week Range
$127.26–234.52
Bid/Ask
$221.64 / $223.30
Market Cap
$23.58 Bil
Volume/Avg
7,315 / 284,535

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
7.57
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene’s key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
9,000
Website
https://www.beigene.com

Competitors

Valuation

View More
Metric
BGNE
ABBV
01801
Price/Earnings (Normalized)
 —18.46—
Price/Book Value
 7.0651.456.53
Price/Sales
 7.576.369.32
Price/Cash Flow
 —18.735,745.18
Price/Earnings
BGNE
ABBV
01801

Financial Strength

Metric
BGNE
ABBV
01801
Quick Ratio
 1.640.592.46
Current Ratio
 1.980.812.68
Interest Coverage
 —3.51−19.08
Quick Ratio
BGNE
ABBV
01801

Profitability

Metric
BGNE
ABBV
01801
Return on Assets (Normalized)
 −2.03%13.66%−2.47%
Return on Equity (Normalized)
 −3.24%189.99%−4.60%
Return on Invested Capital (Normalized)
 −4.24%27.06%−5.53%
Return on Assets
BGNE
ABBV
01801

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
FsvskdqpsGqvfv$524.5 Bil
 Vertex Pharmaceuticals Inc
VRTX
BmqstqhybLpsvr$120.0 Bil
 Regeneron Pharmaceuticals Inc
REGN
YcmvprrjfYdlvcvw$115.9 Bil
 Alnylam Pharmaceuticals Inc
ALNY
FppqtqmkfLfqrw$35.3 Bil
 argenx SE ADR
ARGX
KbgwdbmgKjd$32.4 Bil
 BioNTech SE ADR
BNTX
PfbmccxfMlq$28.2 Bil
 Moderna Inc
MRNA
KmhsmjkqFlnrk$25.7 Bil
 United Therapeutics Corp
UTHR
ZzzvqbbvRvgqd$15.9 Bil
 Biomarin Pharmaceutical Inc
BMRN
PwnfzmzgQvfpnl$13.4 Bil
 Incyte Corp
INCY
QynszdyfdScsvnwp$12.7 Bil

Sponsor Center